EU approves Merck's Keytruda-Padcev regimen for muscle-invasive bladder cancer

Bitget2026/10/21 10:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

European Commission approved Merck’s Keytruda with Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, regardless of cisplatin eligibility.
The Phase 3 KEYNOTE-B15 trial showed a 47% reduction in disease progression, recurrence or death risk versus chemotherapy and surgery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021594617) on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

EU approves Merck's Keytruda-Padcev regimen for muscle-invasive bladder cancer

You may also like

Crypto prices